Literature DB >> 19515085

Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17.

Mark Katakowski1, Feng Jiang, XuGuang Zheng, Jorge A Gutierrez, Alexandra Szalad, Michael Chopp.   

Abstract

The metalloprotease ADAM17 (a.k.a. TACE) plays a pivotal role in the cleavage and activation of membrane-anchored receptor ligands. More recently, it has been revealed that ADAM17 is a potent sheddase of the epidermal growth factor (EGF) family of ligands and regulates epidermal growth factor receptor (EGFR) activity in a variety of tumors. EGFR is a key component of autonomous growth signaling in several tumors, and correlates with the malignancy grade of astrocytoma. In this study, we tested the hypothesis that over-expression of ADAM17 in cortical astrocytes derived from normal brain would induce a progression towards a malignant phenotype. Over-expression of human ADAM17 (hADAM17) in the CTX-TNA2 cortical astrocyte cell line resulted in non-adherent growth, increased proliferation, invasiveness, production of angiogenic factors, and expression of genes associated with immature and/or neoplastic cells. hADAM17 up-regulated EGFR and AKT phosphorylation, and increased proliferation and cell invasion were significantly dependent upon EGFR activity. When implanted in the nude mouse brain, CTX-TNA2 cells induced low histological grade, benign intraventricular gliomas. In contrast, the same astrocytes with hADAM17 formed large malignant gliomas. Taken together, these findings suggest that unregulated ADAM17 activity induces functional changes in astrocytes that significantly advance the malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515085      PMCID: PMC2756136          DOI: 10.1111/j.1349-7006.2009.01221.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  50 in total

1.  HB-EGF promotes angiogenesis in endothelial cells via PI3-kinase and MAPK signaling pathways.

Authors:  Veela B Mehta; Gail E Besner
Journal:  Growth Factors       Date:  2007-08       Impact factor: 2.511

Review 2.  Medulloblastoma stem cells.

Authors:  Xing Fan; Charles G Eberhart
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

3.  Kuz and TACE can activate Notch independent of ligand.

Authors:  A Delwig; M D Rand
Journal:  Cell Mol Life Sci       Date:  2008-07       Impact factor: 9.261

4.  Notch signaling mediates hypoxia-induced tumor cell migration and invasion.

Authors:  Cecilia Sahlgren; Maria V Gustafsson; Shaobo Jin; Lorenz Poellinger; Urban Lendahl
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-21       Impact factor: 11.205

5.  Effect and mechanism of the Twist gene on invasion and metastasis of gastric carcinoma cells.

Authors:  Geng-Qiu Luo; Jing-He Li; Ji-Fang Wen; Yan-Hong Zhou; Yong-Bin Hu; Jian-Hua Zhou
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

6.  The activated Notch1 receptor cooperates with alpha-enolase and MBP-1 in modulating c-myc activity.

Authors:  Kai-Wen Hsu; Rong-Hong Hsieh; Yan-Hwa Wu Lee; Chi-Hong Chao; Kou-Juey Wu; Min-Jen Tseng; Tien-Shun Yeh
Journal:  Mol Cell Biol       Date:  2008-05-19       Impact factor: 4.272

7.  Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17.

Authors:  Cary W Esselens; Jordi Malapeira; Núria Colomé; Marcia Moss; Francesc Canals; Joaquín Arribas
Journal:  Biol Chem       Date:  2008-08       Impact factor: 3.915

Review 8.  Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer.

Authors:  Paraic A Kenny
Journal:  Expert Opin Ther Targets       Date:  2007-10       Impact factor: 6.902

Review 9.  Activation of epidermal growth factor receptors in astrocytes: from development to neural injury.

Authors:  Bin Liu; Arthur H Neufeld
Journal:  J Neurosci Res       Date:  2007-12       Impact factor: 4.164

10.  c-Myc is required for maintenance of glioma cancer stem cells.

Authors:  Jialiang Wang; Hui Wang; Zhizhong Li; Qiulian Wu; Justin D Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  PLoS One       Date:  2008-11-20       Impact factor: 3.240

View more
  11 in total

1.  ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway.

Authors:  Ping Lin; Xicai Sun; Tian Feng; Haifeng Zou; Ying Jiang; Zijun Liu; Dandan Zhao; Xiaoguang Yu
Journal:  Mol Cell Biochem       Date:  2011-08-12       Impact factor: 3.396

Review 2.  ADAM-17: the enzyme that does it all.

Authors:  Monika Gooz
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-04       Impact factor: 8.250

3.  ADAM17 promotes glioma cell malignant phenotype.

Authors:  Xuguang Zheng; Feng Jiang; Mark Katakowski; Yong Lu; Michael Chopp
Journal:  Mol Carcinog       Date:  2011-04-07       Impact factor: 4.784

4.  Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.

Authors:  D Aydin; A Bilici; D Yavuzer; U Kefeli; A Tan; O Ercelep; A Mert; S Yuksel; M Ozcelik; D Isik; H Surmeli; H Odabasi; M Aliustaoglu
Journal:  Clin Transl Oncol       Date:  2015-03-19       Impact factor: 3.405

5.  ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.

Authors:  Xiang-Jun Wang; Chang-Wei Feng; Min Li
Journal:  Mol Cell Biochem       Date:  2013-04-28       Impact factor: 3.396

6.  Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.

Authors:  Jennifer Barrow; Martyna Adamowicz-Brice; Maria Cartmill; Donald MacArthur; James Lowe; Keith Robson; Marie-Anne Brundler; David A Walker; Beth Coyle; Richard Grundy
Journal:  Neuro Oncol       Date:  2010-12-07       Impact factor: 12.300

7.  Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway.

Authors:  Junyan Chen; Xiangrong Chen; Fan Wang; Hongzhi Gao; Weipeng Hu
Journal:  Neurol Sci       Date:  2014-10-10       Impact factor: 3.307

8.  ADAM17 silencing in mouse colon carcinoma cells: the effect on tumoricidal cytokines and angiogenesis.

Authors:  Sudipta Das; Maria Czarnek; Monika Bzowska; Renata Mężyk-Kopeć; Krystyna Stalińska; Barbara Wyroba; Jolanta Sroka; Jarosław Jucha; Dawid Deneka; Paulina Stokłosa; Justyna Ogonek; Melody A Swartz; Zbigniew Madeja; Joanna Bereta
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

9.  MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells.

Authors:  Yong Lu; Michael Chopp; Xuguang Zheng; Mark Katakowski; Benjamin Buller; Feng Jiang
Journal:  Oncol Rep       Date:  2012-10-17       Impact factor: 3.906

10.  Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation.

Authors:  Sung Woo Hong; Wonhee Hur; Jung Eun Choi; Jung-Hee Kim; Daehee Hwang; Seung Kew Yoon
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.